Kanjin Therapeutics is a US and Japan based global biotechnology startup with pioneering interventions to restore kidney function and transform the treatment of chronic kidney diseases. Founded as a scientific spinout from Okayama University (Japan), Kanjin unites world-class expertise in kidney biology and translational medicine.
Our name reflects both our science and our mission. Kanjin combines 肝臓 (Kanzō, liver) and 腎臓 (Jinzō, kidney), underscoring our unique strategy of targeting the liver to restore kidney function. At the same time, 肝腎 (Kanjin) means “the essential core meaning,” capturing our focus on what matters most: making kidney disease a curable condition.
Our Leadership
Takehiko Sawabe, MS, MBA
Director and President
Caleb B. Bell III, PhD
Founder, Director and CEO
Masanori Nakayama, PhD
Scientific Founder, Director and Chairman of the
Scientific Advisory Board
Meet Our Scientific Advisory Board
Masanori Nakayama, PhD
Founding Scientist, Director and
Chair of SAB of Kanjin
Professor Medicine, Dentistry and Pharmaceutical Sciences at
Okayama University
Kirk Campbell, MD
Attending Physician, Professor and
Chief of the Renal Division at the
University of Pennsylvania
President of the National Kidney
Foundation
Christian Mende, MD
Attending Physician and
Clinical Professor of
Medicine at UC San Diego
Takao Hikita, PhD
Founding Scientist and Member
of SAB for Kanjin
Associate Professor at Okayama
University
Our Partners
